Jacobs Bruce N.: insider trades.
Jacobs Bruce N. reported 9 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($8.9M), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 8
- Companies
- 1
- Name as filed
- Jacobs Bruce N.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | Officer · Chief Financial Officer | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 1,100 | $112.79 | 317,692 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 4,110 | $114.19 | 313,582 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 51,375 | $114.77 | 262,207 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 1,700 | $111.57 | 318,792 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 1,500 | $110.54 | 320,492 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | M | 61,378 | $5.33 | 321,992 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 7,971 | $115.82 | 254,236 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 3,200 | $117.7 | 244,883 | Form 4 |
| 2026-06-30 | Kymera Therapeutics, Inc. | S | 6,153 | $116.99 | 248,083 | Form 4 |
Questions
What stock did Jacobs Bruce N. buy or sell?
Jacobs Bruce N. reported 9 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($8.9M), across 1 company.
Is Jacobs Bruce N. the same person as other filers with this name?
This page covers SEC CIK 1821074 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/jacobs-bruce-n-1821074.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.